A recombinant, fully human monoclonal antibody with antitumor activity constructed from phage-displayed antibody fragments

[1]  H. A. Bakker,et al.  Cytoplasmic Tail Regulates the Intercellular Adhesion Function of the Epithelial Cell Adhesion Molecule , 1998, Molecular and Cellular Biology.

[2]  R. Levy,et al.  Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  D Tripathy,et al.  Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  J. Osbourn,et al.  Human antibodies by design , 1998, Nature Biotechnology.

[5]  Larry L. Green,et al.  Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice , 1997, Nature Genetics.

[6]  G. Storm,et al.  Biosynthetically lipid‐modified human scFv fragments from phage display libraries as targeting molecules for immunoliposomes , 1996, FEBS letters.

[7]  M. Neuberger,et al.  Strategies for expressing human antibody repertoires in transgenic mice. , 1996, Immunology today.

[8]  G. Fleuren,et al.  The role of monoclonal antibody affinity in tumor immunotherapy evaluated in in vivo models for minimal residual disease. , 1996, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[9]  J. Hale.  Irreversible, oriented immobilization of antibodies to cobalt-iminodiacetate resin for use as immunoaffinity media. , 1995, Analytical biochemistry.

[10]  A. Nesbitt,et al.  Comprehensive pharmacokinetics of a humanized antibody and analysis of residual anti-idiotypic responses. , 1995, Immunology.

[11]  L. Terstappen,et al.  Rapid selection of cell subpopulation-specific human monoclonal antibodies from a synthetic phage antibody library. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[12]  T. Logtenberg,et al.  Selection and application of human single chain Fv antibody fragments from a semi-synthetic phage antibody display library with designed CDR3 regions. , 1995, Journal of molecular biology.

[13]  George Georgiou,et al.  Construction and Characterization of a Set of E. coli Strains Deficient in All Known Loci Affecting the Proteolytic Stability of Secreted Recombinant Proteins , 1994, Bio/Technology.

[14]  J. Woody,et al.  Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis , 1994, The Lancet.

[15]  G. Riethmüller,et al.  Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma , 1994, The Lancet.

[16]  H. A. Bakker,et al.  Ep-CAM: a human epithelial antigen is a homophilic cell-cell adhesion molecule , 1994, The Journal of cell biology.

[17]  J. Kalden,et al.  Involvement of the high-affinity receptor for IgG (Fc gamma RI; CD64) in enhanced tumor cell cytotoxicity of neutrophils during granulocyte colony-stimulating factor therapy , 1993 .

[18]  G. Winter,et al.  Antibody framework residues affecting the conformation of the hypervariable loops. , 1992, Journal of molecular biology.

[19]  R. Karlsson,et al.  Kinetic analysis of monoclonal antibody-antigen interactions with a new biosensor based analytical system. , 1991, Journal of immunological methods.

[20]  J. Schlom,et al.  Pharmacokinetics and immune response of 131I-chimeric mouse/human B72.3 (human gamma 4) monoclonal antibody in humans. , 1991, Cancer research.

[21]  P. Familletti,et al.  Reduced immunogenicity and improved pharmacokinetics of humanized anti-Tac in cynomolgus monkeys. , 1991, Journal of immunology.

[22]  K. Isselbacher,et al.  Epithelial glycoprotein is a member of a family of epithelial cell surface antigens homologous to nidogen, a matrix adhesion protein. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[23]  W. P. Schneider,et al.  Anti-Tac-H, a humanized antibody to the interleukin 2 receptor with new features for immunotherapy in malignant and immune disorders. , 1990, Cancer research.

[24]  C. Anderson,et al.  Human IgG Fc receptors. , 1989, Clinical immunology and immunopathology.

[25]  J. Verhoef,et al.  Complement-mediated phagocytosis of herpes simplex virus by granulocytes. Binding or ingestion. , 1989, The Journal of clinical investigation.

[26]  J. Ghrayeb,et al.  Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[27]  R. Jefferis,et al.  Aglycosylation of human IgG1 and IgG3 monoclonal antibodies can eliminate recognition by human cells expressing Fc gamma RI and/or Fc gamma RII receptors. , 1989, The Biochemical journal.

[28]  J. Ng,et al.  Biochemical analysis of a human epithelial surface antigen: differential cell expression and processing. , 1988, Archives of biochemistry and biophysics.

[29]  J. Ghrayeb,et al.  Biological activity of human-mouse IgG1, IgG2, IgG3, and IgG4 chimeric monoclonal antibodies with antitumor specificity. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[30]  Lutz Riechmann,et al.  Reshaping human antibodies for therapy , 1988, Nature.

[31]  P. Möller,et al.  Immunohistochemical study of the expression of a Mr 34,000 human epithelium-specific surface glycoprotein in normal and malignant tissues. , 1987, Cancer research.

[32]  R. R. Robinson,et al.  Chimeric mouse-human IgG1 antibody that can mediate lysis of cancer cells. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[33]  R. Ueda,et al.  Recombinant human-mouse chimeric monoclonal antibody specific for common acute lymphocytic leukemia antigen. , 1987, Cancer research.

[34]  G. Riethmüller,et al.  The epithelial cell surface antigen 17–1A, a target for antibody‐mediated tumor therapy: Its biochemical nature, tissue distribution and recognition by different monoclonal antibodies , 1986, International journal of cancer.

[35]  L. M. Smith,et al.  Human immune response to multiple injections of murine monoclonal IgG. , 1985, Journal of immunology.

[36]  J. Wands,et al.  Inhibition of hepatic metastases of human colon cancer in nude mice by a chimeric SF-25 monoclonal antibody. , 1995, Gastroenterology.

[37]  G. Winter,et al.  Making antibodies by phage display technology. , 1994, Annual review of immunology.

[38]  R. Stein,et al.  SCLC‐cluster‐2 antibodies detect the pancarcinoma/epithelial glycoprotein EGP‐2 , 1994, International journal of cancer. Supplement = Journal international du cancer. Supplement.

[39]  D R Burton,et al.  Human antibodies from combinatorial libraries. , 1994, Advances in immunology.

[40]  P. Daddona,et al.  Evaluation of the 323/A3 monoclonal antibody and the use of technetium-99m-labeled 323/A3 Fab' for the detection of pan adenocarcinoma. , 1991, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.

[41]  P. T. Jones,et al.  Replacing the complementarity-determining regions in a human antibody with those from a mouse , 1986, Nature.

[42]  R. Levy,et al.  Monoclonal antibody therapeutic trials in seven patients with T-cell lymphoma. , 1983, Blood.